At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pegetron® Redipen™ Prospective Optimal Weight-based Dosing Response Program
In Brief
An observational study evaluating PegIFN-2b and Ribavirin for Hepatitis C, Chronic and Hepatitis C. Completed, enrolled 2,430 participants.
Detailed Summary
Treatment compliance is a key success factor in obtaining the full benefit of Pegetron (peginterferon alfa-2b \[PegIFN-2b\] plus ribavirin combination) therapy for patients. Treatment-naïve patients with chronic hepatitis C (CHC) in Canada to whom Pegetron Redipen was prescribed will receive Pegetron Redipen therapy in accordance with approved labeling. The study will assess the effect of the newly approved Pegetron Redipen on treatment compliance and its effect on sustained virologic response rates. Sustained virologic response is defined as negative hepatitis C virus ribonucleic acid (HCV-RNA) six months post-treatment.
Study Details
Timeline
Interventions
PegIFN-2b powder for solution adminstered subcutaneously using the newly approved Redipen. Dosing per approved labeling
Ribavirin capsules administered orally. Dosing in accordance with approved labelling.